Alzamend Neuro Completes Phase II Brain Imaging Study of Novel Lithium Therapy AL001
Key Insights
Alzamend Neuro has completed the clinical portion of its Phase II study of AL001, a novel lithium-delivery system designed to improve brain (search) penetration while reducing systemic side effects.
The study utilized advanced brain (search) imaging technology to compare AL001's lithium distribution versus conventional lithium carbonate in healthy subjects at Massachusetts General Hospital.
AL001 aims to eliminate the need for therapeutic drug monitoring by achieving superior brain (search) uptake with lower blood lithium levels, potentially transforming treatment for neuropsychiatric disorders.
Alzamend Neuro has completed the clinical portion of its Phase II study evaluating AL001, a novel lithium-delivery system designed to enhance brain (search) penetration while minimizing systemic toxicity. The study, conducted at Massachusetts General Hospital, represents a significant milestone in developing next-generation lithium therapy that could eliminate the need for therapeutic drug monitoring.
Advanced Brain Imaging Technology Enables Precise Lithium Quantification
The clinical study utilized a unique engineered head coil developed by Tesla Dynamic Coils BV (search), enabling high-resolution, whole-brain (search) lithium imaging. This technology allows for precise quantification of lithium within specific brain structures, providing proprietary imaging datasets that will establish foundational references for optimal, disease-specific target doses of AL001.
The primary objective focused on assessing how AL001 delivers lithium to the brain (search) compared to marketed lithium salts, evaluating its ability to achieve better therapeutic efficacy while minimizing systemic side effects. Head-to-head studies compared AL001 versus a marketed lithium carbonate product for lithium blood and brain pharmacokinetics in healthy subjects.
Addressing Critical Limitations of Current Lithium Therapy
Lithium is widely recognized as a highly effective first-line option for managing manic episodes and maintenance in bipolar disorder (search), yet its adoption has been limited by therapeutic drug monitoring challenges. Lithium salts approved by the U.S. Food and Drug Administration currently face a narrow therapeutic index, necessitating frequent clinician-monitored plasma lithium and blood chemistry tests to prevent adverse effects.
Through reduced systemic exposure, AL001 may represent a paradigm shift in treating disorders such as Alzheimer's disease (search) by lowering the risks of kidney and thyroid complications commonly associated with conventional lithium regimens. Prior research in mice demonstrated that AL001 achieves superior brain (search) uptake while keeping blood lithium levels lower, setting the stage for safer and more effective therapies.
Novel Ionic Cocrystal Technology
AL001 is a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate and L-proline. The formulation is designed to favorably distribute lithium in the brain (search), resulting in lower exposure of other body organs and an improved safety profile compared to currently marketed lithium salts.
Results from Alzamend's completed Phase IIA multiple-ascending dose study of AL001 in Alzheimer's patients and healthy subjects identified a maximum tolerated dose, as assessed by an independent safety review committee. This maximum tolerated dose is designed to be unlikely to require therapeutic drug monitoring while providing lithium at a relatively modest but effective dose.
Clinical Development Timeline and Future Plans
"The completion of the clinical portion of our Phase II trial of AL001 marks a pivotal milestone in our mission to deliver a next-generation lithium therapy with improved safety, superior brain (search) penetration, and no need for TDM," said Stephan Jackman, Chief Executive Officer of Alzamend.
Topline data is expected in the first quarter of 2026. The imaging data will inform planned Phase II clinical trials in Alzheimer's disease (search), bipolar disorder (search), major depressive disorder (search), and post-traumatic stress disorder (search), which are all expected to be initiated next year. These findings are anticipated to confirm that AL001 offers a superior balance of safety and efficacy compared to conventional lithium carbonate.
By potentially removing the requirement for lithium therapeutic drug monitoring, AL001 could transform treatment for at-risk patient groups and enhance clinical outcomes across multiple neuropsychiatric conditions.